Welcome to LookChem.com Sign In|Join Free

CAS

  • or

14899-36-6

Post Buying Request

14899-36-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

14899-36-6 Usage

Description

Dexamethasone palmitate (DXP) is a corticosteroid prodrug derived from dexamethasone, a steroidal anti-inflammatory drug used to treat various pain and inflammatory conditions such as asthma and rheumatoid arthritis. It is formulated as a colorless thick oil and is specifically designed to increase the distribution of dexamethasone in the lungs for local drug delivery, while preventing its entry into the systemic circulation. The prodrug is metabolized by esterase enzyme within the lungs, leading to the release of the parent drug and enhancing its distribution within the lungs.

Uses

Used in Pharmaceutical Industry:
Dexamethasone palmitate is used as a corticosteroid prodrug for the treatment of eye disorders, providing targeted anti-inflammatory effects to the ocular region.
Used in Respiratory Applications:
Dexamethasone palmitate is used as a prodrug for the treatment of respiratory conditions, such as asthma and other inflammatory lung diseases. Administered via the pulmonary route, it allows for local drug delivery within the lungs, reducing systemic side effects and increasing the therapeutic efficacy of dexamethasone.
Used in Drug Delivery Systems:
Dexamethasone palmitate is utilized in the development of novel drug delivery systems to enhance the bioavailability and therapeutic outcomes of dexamethasone. By employing various carriers, such as organic and metallic nanoparticles, the prodrug can be effectively delivered to target sites, improving its overall efficacy and reducing potential side effects.

Biochem/physiol Actions

Dexamethasone Palmitate is a lipophilic prodrug of a potent corticosteroid dexamethasone that is quickly taking up by macrophages via phagocytosis. Dexamethasone Palmitate inhibits function and migration of leukocytes and tissue macrophages.

Check Digit Verification of cas no

The CAS Registry Mumber 14899-36-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,8,9 and 9 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 14899-36:
(7*1)+(6*4)+(5*8)+(4*9)+(3*9)+(2*3)+(1*6)=146
146 % 10 = 6
So 14899-36-6 is a valid CAS Registry Number.
InChI:InChI=1/C38H59FO6/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-34(43)45-26-33(42)38(44)27(2)23-31-30-20-19-28-24-29(40)21-22-35(28,3)37(30,39)32(41)25-36(31,38)4/h21-22,24,27,30-32,41,44H,5-20,23,25-26H2,1-4H3/t27-,30+,31+,32+,35+,36+,37+,38+/m1/s1

14899-36-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name Dexamethasone 21-Palmitate

1.2 Other means of identification

Product number -
Other names DXM-21-palmitate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:14899-36-6 SDS

14899-36-6Synthetic route

hexadecanoic acid methyl ester
112-39-0

hexadecanoic acid methyl ester

dexamethasone
50-02-2

dexamethasone

dexamethasone palmitate
14899-36-6

dexamethasone palmitate

Conditions
ConditionsYield
With ceria-doped alumina at 40 - 80℃; under 525.053 Torr; for 3h; Reagent/catalyst; Pressure; Temperature; Inert atmosphere;92%
dexamethasone palmitate
14899-36-6

dexamethasone palmitate

human low density protein

human low density protein

oxidized dexamethasone palmitate-human low density lipoprotein complex

oxidized dexamethasone palmitate-human low density lipoprotein complex

Conditions
ConditionsYield
Stage #1: dexamethasone palmitate; human low density protein With Celite at 37℃; for 20h; Complex formation;
Stage #2: With copper(II) sulfate at 37℃; for 20h; Oxidation;

14899-36-6Downstream Products

14899-36-6Relevant articles and documents

Synthesis method of dexamethasone palmitate

-

Paragraph 0035-0046, (2019/08/03)

The invention relates to a synthesis method of dexamethasone palmitate. The method comprises the steps as follows: dexamethasone and methyl palmitate are subjected to transesterification under catalysis of solid alkali and a phase transfer catalyst to obtain a target product; a mixture of methyl palmitate and the product obtained after a solvent is removed from solid alkali and the phase transfercatalyst by evaporation is recycled. The method is mild in reaction condition, green, environmentally friendly, simple, efficient and energy-saving, raw materials are easy to obtain, the production cost is reduced, the operation environment is improved, and the method is convenient to operate, high in automation degree and particularly prone to industrialization.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 14899-36-6